Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ralinepag - United Therapeutics Corporation

Next Previous
X
Search
Drug Profile

Ralinepag - United Therapeutics Corporation

Alternative Names: APD-811

Latest Information Update: 28 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arena Pharmaceuticals
  • Developer United Therapeutics Corporation
  • Class Acetic acids; Antihypertensives; Benzene derivatives; Carbamates; Chlorobenzenes; Cyclohexanes; Ethers; Small molecules
  • Mechanism of Action Epoprostenol receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pulmonary arterial hypertension

Most Recent Events

  • 17 May 2024 Interim efficacy and adverse events data from a phase III OLE trial in Pulmonary arterial hypertension presented at the 120th International Conference of the American Thoracic Society (ATS-2024)
  • 02 Aug 2023 United Therapeutics Corporation plans to launch ralinepag in pulmonary arterial hypertension
  • 29 Nov 2022 Phase-III development is ongoing Argentina, Australia, Belgium, Bulgaria, Canada, China, Croatia, Denmark, France, Germany, Greece, Hungary, Italy, Netherlands, Spain, Sweden, Ukraine, Taiwan, Brazil, Czech Republic, Israel, South Korea, Poland, Singapore, United Kingdom, Austria, USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top